Jane Street’s Relmada Therapeutics RLMD Stock Holding History

Jane Street’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$75.9K	Sell	10,900 -1,300	-11%	-$6.15K	﹤0.01%	10774
2025 Q4	$58.9K	Buy	+12,200	New	+$40.9K	﹤0.01%	10451
2023 Q1	–	Sell	-218,500	Closed	-$763K	–	9779
2022 Q4	$763K	Sell	218,500 -150,600	-41%	-$1.32M	﹤0.01%	5437
2022 Q3	$13.7M	Buy	369,100 +358,800	+3,483%	+$9.94M	0.01%	1407
2022 Q2	$196K	Sell	10,300 -24,300	-70%	-$530K	﹤0.01%	8207
2022 Q1	$934K	Buy	+34,600	New	+$715K	﹤0.01%	6277
2021 Q1	–	Sell	-28,300	Closed	-$908K	–	9510
2020 Q4	$908K	Buy	+28,300	New	+$972K	﹤0.01%	4817
2020 Q3	–	Sell	-44,900	Closed	-$2.01M	–	7798
2020 Q2	$2.01M	Buy	+44,900	New	+$1.9M	﹤0.01%	3059

Other funds holding RLMD

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

SSC

Spruce Street Capital New York $416M AUM

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Jane Street's RLMD Position: Q1 2026 in Review

Jane Street reduced its Relmada Therapeutics (RLMD) stake by 18% in Q1 2026, selling an estimated $232K and leaving 221,969 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #5577.

Jane Street first reported a position in RLMD in Q1 2020 and has held it in 14 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

Jane Street held 221,969 shares of Relmada Therapeutics worth $1.54M as of Q1 2026.
Jane Street sold 49,140 Relmada Therapeutics shares in Q1 2026, an estimated $232K.
Relmada Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5577 holding.
Jane Street first reported a position in Relmada Therapeutics in Q1 2020 and has held it in 14 quarters since.
103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.